- Home
- MDGL vs PODD Comparison
MDGL vs PODD Comparison
Compare MDGL & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDGL | PODD |
|---|---|---|
| Founded | 2011 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1B | 10.5B |
| IPO Year | 2005 | 2007 |
Fundamental Metrics
Financial Performance| Metric | MDGL | PODD |
|---|---|---|
| Price | $497.82 | $158.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 21 |
| Target Price | ★ $674.45 | $341.48 |
| AVG Volume (30 Days) | 254.7K | ★ 1.4M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.32 | N/A |
| EPS | N/A | ★ 1.30 |
| Revenue | $180,133,000.00 | ★ $2,708,100,000.00 |
| Revenue This Year | $58.39 | $24.55 |
| Revenue Next Year | $48.55 | $19.18 |
| P/E Ratio | ★ N/A | $118.53 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $265.00 | $148.31 |
| 52 Week High | $615.00 | $354.88 |
Technical Indicators
Market Signals| Indicator | MDGL | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 44.46 | 33.03 |
| Support Level | $461.99 | N/A |
| Resistance Level | $502.97 | $205.95 |
| Average True Range (ATR) | 20.67 | 8.61 |
| MACD | -4.06 | -1.07 |
| Stochastic Oscillator | 12.36 | 23.26 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.